OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial

NEXT STORY
Athenex Announces Expansion of Board of Directors
PREV STORY
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors

author_avatar
NASDAQ Market News

FDA Grants Pediatric Disease Designation for Mateon’s CA4P

author_avatar
NASDAQ Market News

Takeda en TiGenix maken resultaten bekend van tweede acceptatieperiode voor het vrijwillige en voorwaardelijke openbare overnamebod van TiGenix

                    PERSBERICHT Takeda en TiGenix maken resultaten bekend van tweede acceptatieperiode voor het vrijwillige ...

author_avatar
NASDAQ Market News